RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) Trading Up 8.9%

Shares of RegeneRx Biopharmaceuticals, Inc. (OTCMKTS:RGRXGet Rating) shot up 8.9% during trading on Wednesday . The stock traded as high as $0.17 and last traded at $0.16. 153,390 shares were traded during trading, an increase of 238% from the average session volume of 45,406 shares. The stock had previously closed at $0.15.

RegeneRx Biopharmaceuticals Stock Performance

The company’s 50-day moving average price is $0.16 and its 200 day moving average price is $0.17.

RegeneRx Biopharmaceuticals Company Profile

(Get Rating)

RegeneRx Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue.

Recommended Stories

Receive News & Ratings for RegeneRx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RegeneRx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.